D
PharmaCyte Biotech, Inc.
PMCB
$1.64
-$0.12-6.82%
D
Sell
2/13/2025Downgrade
PharmaCyte Biotech, Inc. (PMCB) was downgraded to D from D+ on 2/13/2025 due to a decline in the efficiency index.
PharmaCyte Biotech, Inc. (PMCB) was downgraded to D from D+ on 2/13/2025 due to a decline in the efficiency index.
D
Sell
1/29/2025Upgraded
PharmaCyte Biotech, Inc. (PMCB) was upgraded to D+ from D on 1/29/2025 due to an increase in the volatility index and total return index.
PharmaCyte Biotech, Inc. (PMCB) was upgraded to D+ from D on 1/29/2025 due to an increase in the volatility index and total return index.
D
Sell
1/14/2025Downgrade
PharmaCyte Biotech, Inc. (PMCB) was downgraded to D from D+ on 1/14/2025 due to a decline in the volatility index.
PharmaCyte Biotech, Inc. (PMCB) was downgraded to D from D+ on 1/14/2025 due to a decline in the volatility index.
D
Sell
12/30/2024Upgraded
PharmaCyte Biotech, Inc. (PMCB) was upgraded to D+ from D on 12/30/2024 due to an increase in the volatility index.
PharmaCyte Biotech, Inc. (PMCB) was upgraded to D+ from D on 12/30/2024 due to an increase in the volatility index.
D
Sell
12/13/2024Downgrade
PharmaCyte Biotech, Inc. (PMCB) was downgraded to D from D+ on 12/13/2024 due to a major decline in the growth index and solvency index. Operating cash flow declined 182.53% from -$373.3 to -$1.05M, earnings per share declined from $2.182 to -$0.39, and the quick ratio declined from 4.37 to 4.36.
PharmaCyte Biotech, Inc. (PMCB) was downgraded to D from D+ on 12/13/2024 due to a major decline in the growth index and solvency index. Operating cash flow declined 182.53% from -$373.3 to -$1.05M, earnings per share declined from $2.182 to -$0.39, and the quick ratio declined from 4.37 to 4.36.
D
Sell
9/18/2024Upgraded
PharmaCyte Biotech, Inc. (PMCB) was upgraded to D+ from D on 9/18/2024 due to a significant increase in the valuation index, efficiency index and growth index. Net income increased 1,639.17% from $1.35M to $23.42M, earnings per share increased from -$0.3042 to $1.9015, and total capital increased 16.97% from $45.35M to $53.04M.
PharmaCyte Biotech, Inc. (PMCB) was upgraded to D+ from D on 9/18/2024 due to a significant increase in the valuation index, efficiency index and growth index. Net income increased 1,639.17% from $1.35M to $23.42M, earnings per share increased from -$0.3042 to $1.9015, and total capital increased 16.97% from $45.35M to $53.04M.
D
Sell
8/19/2024Upgraded
PharmaCyte Biotech, Inc. (PMCB) was upgraded to D from E+ on 8/19/2024 due to a substantial increase in the efficiency index, growth index and total return index. Net income increased 317.38% from -$619.5 to $1.35M, earnings per share increased from -$0.653 to -$0.3042, and EBIT increased 37.6% from -$1.87M to -$1.17M.
PharmaCyte Biotech, Inc. (PMCB) was upgraded to D from E+ on 8/19/2024 due to a substantial increase in the efficiency index, growth index and total return index. Net income increased 317.38% from -$619.5 to $1.35M, earnings per share increased from -$0.653 to -$0.3042, and EBIT increased 37.6% from -$1.87M to -$1.17M.
E
Sell
11/15/2023Downgrade
PharmaCyte Biotech, Inc. (PMCB) was downgraded to E+ from D- on 11/15/2023 due to a decline in the volatility index and growth index.
PharmaCyte Biotech, Inc. (PMCB) was downgraded to E+ from D- on 11/15/2023 due to a decline in the volatility index and growth index.
D
Sell
10/31/2023Upgraded
PharmaCyte Biotech, Inc. (PMCB) was upgraded to D- from E+ on 10/31/2023 due to an increase in the volatility index and valuation index.
PharmaCyte Biotech, Inc. (PMCB) was upgraded to D- from E+ on 10/31/2023 due to an increase in the volatility index and valuation index.
E
Sell
3/14/2023Downgrade
PharmaCyte Biotech, Inc. (PMCB) was downgraded to E+ from D on 3/14/2023 due to a decline in the volatility index.
PharmaCyte Biotech, Inc. (PMCB) was downgraded to E+ from D on 3/14/2023 due to a decline in the volatility index.
D
Sell
2/9/2023Upgraded
PharmaCyte Biotech, Inc. (PMCB) was upgraded to D from E+ on 2/9/2023 due to an increase in the volatility index and total return index.
PharmaCyte Biotech, Inc. (PMCB) was upgraded to D from E+ on 2/9/2023 due to an increase in the volatility index and total return index.
E
Sell
2/8/2023Downgrade
PharmaCyte Biotech, Inc. (PMCB) was downgraded to E+ from D on 02/08/2023.
PharmaCyte Biotech, Inc. (PMCB) was downgraded to E+ from D on 02/08/2023.
D
Sell
12/30/2022Upgraded
PharmaCyte Biotech, Inc. (PMCB) was upgraded to D from D- on 12/30/2022 due to an increase in the total return index.
PharmaCyte Biotech, Inc. (PMCB) was upgraded to D from D- on 12/30/2022 due to an increase in the total return index.
D
Sell
12/15/2022Downgrade
PharmaCyte Biotech, Inc. (PMCB) was downgraded to D- from D on 12/15/2022 due to a decline in the growth index, solvency index and volatility index. Operating cash flow declined 73.3% from -$1.08M to -$1.88M, EBIT declined 37.96% from -$1.68M to -$2.32M, and earnings per share declined from -$0.0742 to -$0.0914.
PharmaCyte Biotech, Inc. (PMCB) was downgraded to D- from D on 12/15/2022 due to a decline in the growth index, solvency index and volatility index. Operating cash flow declined 73.3% from -$1.08M to -$1.88M, EBIT declined 37.96% from -$1.68M to -$2.32M, and earnings per share declined from -$0.0742 to -$0.0914.
D
Sell
11/10/2022Upgraded
PharmaCyte Biotech, Inc. (PMCB) was upgraded to D from D- on 11/10/2022 due to an increase in the volatility index, total return index and growth index. Operating cash flow increased 9.01% from -$1.19M to -$1.08M.
PharmaCyte Biotech, Inc. (PMCB) was upgraded to D from D- on 11/10/2022 due to an increase in the volatility index, total return index and growth index. Operating cash flow increased 9.01% from -$1.19M to -$1.08M.
D
Sell
8/1/2022Downgrade
PharmaCyte Biotech, Inc. (PMCB) was downgraded to D- from D on 8/1/2022 due to a noticeable decline in the growth index, solvency index and volatility index. Operating cash flow declined 299.13% from -$298.6 to -$1.19M, EBIT declined 76.11% from -$856.1 to -$1.51M, and earnings per share declined from -$0.04 to -$0.0663.
PharmaCyte Biotech, Inc. (PMCB) was downgraded to D- from D on 8/1/2022 due to a noticeable decline in the growth index, solvency index and volatility index. Operating cash flow declined 299.13% from -$298.6 to -$1.19M, EBIT declined 76.11% from -$856.1 to -$1.51M, and earnings per share declined from -$0.04 to -$0.0663.
D
Sell
7/27/2022Upgraded
PharmaCyte Biotech, Inc. (PMCB) was upgraded to D from D- on 7/27/2022 due to an increase in the total return index and volatility index.
PharmaCyte Biotech, Inc. (PMCB) was upgraded to D from D- on 7/27/2022 due to an increase in the total return index and volatility index.
D
Sell
7/11/2022Downgrade
PharmaCyte Biotech, Inc. (PMCB) was downgraded to D- from D on 7/11/2022 due to a decline in the volatility index.
PharmaCyte Biotech, Inc. (PMCB) was downgraded to D- from D on 7/11/2022 due to a decline in the volatility index.
D
Sell
6/21/2022Upgraded
PharmaCyte Biotech, Inc. (PMCB) was upgraded to D from D- on 6/21/2022 due to an increase in the volatility index.
PharmaCyte Biotech, Inc. (PMCB) was upgraded to D from D- on 6/21/2022 due to an increase in the volatility index.
D
Sell
6/3/2022Downgrade
PharmaCyte Biotech, Inc. (PMCB) was downgraded to D- from D on 6/3/2022 due to a decline in the total return index and volatility index.
PharmaCyte Biotech, Inc. (PMCB) was downgraded to D- from D on 6/3/2022 due to a decline in the total return index and volatility index.
D
Sell
5/17/2022Upgraded
PharmaCyte Biotech, Inc. (PMCB) was upgraded to D from E+ on 5/17/2022 due to an increase in the volatility index.
PharmaCyte Biotech, Inc. (PMCB) was upgraded to D from E+ on 5/17/2022 due to an increase in the volatility index.
E
Sell
5/13/2022Downgrade
PharmaCyte Biotech, Inc. (PMCB) was downgraded to E+ from D on 5/13/2022 due to a decline in the volatility index and total return index.
PharmaCyte Biotech, Inc. (PMCB) was downgraded to E+ from D on 5/13/2022 due to a decline in the volatility index and total return index.
D
Sell
5/4/2022Upgraded
PharmaCyte Biotech, Inc. (PMCB) was upgraded to D from E+ on 5/4/2022 due to an increase in the volatility index and total return index.
PharmaCyte Biotech, Inc. (PMCB) was upgraded to D from E+ on 5/4/2022 due to an increase in the volatility index and total return index.
E
Sell
5/1/2022Downgrade
PharmaCyte Biotech, Inc. (PMCB) was downgraded to E+ from D on 5/1/2022 due to a decline in the volatility index.
PharmaCyte Biotech, Inc. (PMCB) was downgraded to E+ from D on 5/1/2022 due to a decline in the volatility index.
D
Sell
4/27/2022Upgraded
PharmaCyte Biotech, Inc. (PMCB) was upgraded to D from E+ on 4/27/2022 due to an increase in the total return index.
PharmaCyte Biotech, Inc. (PMCB) was upgraded to D from E+ on 4/27/2022 due to an increase in the total return index.
E
Sell
4/20/2022Downgrade
PharmaCyte Biotech, Inc. (PMCB) was downgraded to E+ from D- on 4/20/2022 due to a decline in the volatility index, solvency index and valuation index. The quick ratio declined from 467.11 to 141.34.
PharmaCyte Biotech, Inc. (PMCB) was downgraded to E+ from D- on 4/20/2022 due to a decline in the volatility index, solvency index and valuation index. The quick ratio declined from 467.11 to 141.34.
D
Sell
3/7/2022Downgrade
PharmaCyte Biotech, Inc. (PMCB) was downgraded to D- from D on 3/7/2022 due to a decline in the volatility index.
PharmaCyte Biotech, Inc. (PMCB) was downgraded to D- from D on 3/7/2022 due to a decline in the volatility index.
D
Sell
2/17/2022Upgraded
PharmaCyte Biotech, Inc. (PMCB) was upgraded to D from D- on 2/17/2022 due to an increase in the solvency index, volatility index and total return index. The quick ratio increased from 1.04 to 467.11.
PharmaCyte Biotech, Inc. (PMCB) was upgraded to D from D- on 2/17/2022 due to an increase in the solvency index, volatility index and total return index. The quick ratio increased from 1.04 to 467.11.
D
Sell
11/23/2021Upgraded
PharmaCyte Biotech, Inc. (PMCB) was upgraded to D- from E+ on 11/23/2021 due to an increase in the valuation index.
PharmaCyte Biotech, Inc. (PMCB) was upgraded to D- from E+ on 11/23/2021 due to an increase in the valuation index.
E
Sell
11/8/2021Downgrade
PharmaCyte Biotech, Inc. (PMCB) was downgraded to E+ from D- on 11/8/2021 due to a decline in the total return index, volatility index and growth index. Operating cash flow declined 32% from -$940.3 to -$1.24M, and earnings per share declined from -$0.609 to -$0.6444.
PharmaCyte Biotech, Inc. (PMCB) was downgraded to E+ from D- on 11/8/2021 due to a decline in the total return index, volatility index and growth index. Operating cash flow declined 32% from -$940.3 to -$1.24M, and earnings per share declined from -$0.609 to -$0.6444.
D
Sell
7/9/2021Downgrade
PharmaCyte Biotech, Inc. (PMCB) was downgraded to D- from D on 7/9/2021 due to a decline in the volatility index, total return index and valuation index.
PharmaCyte Biotech, Inc. (PMCB) was downgraded to D- from D on 7/9/2021 due to a decline in the volatility index, total return index and valuation index.
D
Sell
3/12/2021Upgraded
PharmaCyte Biotech, Inc. (PMCB) was upgraded to D from D- on 3/12/2021 due to a noticeable increase in the volatility index, total return index and solvency index.
PharmaCyte Biotech, Inc. (PMCB) was upgraded to D from D- on 3/12/2021 due to a noticeable increase in the volatility index, total return index and solvency index.
D
Sell
3/9/2021Downgrade
PharmaCyte Biotech, Inc. (PMCB) was downgraded to D- from D on 3/9/2021 due to a noticeable decline in the volatility index.
PharmaCyte Biotech, Inc. (PMCB) was downgraded to D- from D on 3/9/2021 due to a noticeable decline in the volatility index.
D
Sell
2/22/2021Upgraded
PharmaCyte Biotech, Inc. (PMCB) was upgraded to D from D- on 2/22/2021 due to an increase in the volatility index.
PharmaCyte Biotech, Inc. (PMCB) was upgraded to D from D- on 2/22/2021 due to an increase in the volatility index.
D
Sell
1/29/2021Downgrade
PharmaCyte Biotech, Inc. (PMCB) was downgraded to D- from D on 1/29/2021 due to a decline in the valuation index.
PharmaCyte Biotech, Inc. (PMCB) was downgraded to D- from D on 1/29/2021 due to a decline in the valuation index.
D
Sell
1/14/2021Upgraded
PharmaCyte Biotech, Inc. (PMCB) was upgraded to D from D- on 1/14/2021 due to an increase in the volatility index and total return index.
PharmaCyte Biotech, Inc. (PMCB) was upgraded to D from D- on 1/14/2021 due to an increase in the volatility index and total return index.
D
Sell
12/30/2020Downgrade
PharmaCyte Biotech, Inc. (PMCB) was downgraded to D- from D on 12/30/2020 due to a decline in the volatility index.
PharmaCyte Biotech, Inc. (PMCB) was downgraded to D- from D on 12/30/2020 due to a decline in the volatility index.
D
Sell
12/11/2020Upgraded
PharmaCyte Biotech, Inc. (PMCB) was upgraded to D from D- on 12/11/2020 due to a noticeable increase in the solvency index and volatility index. The quick ratio increased from 1.88 to 5.78.
PharmaCyte Biotech, Inc. (PMCB) was upgraded to D from D- on 12/11/2020 due to a noticeable increase in the solvency index and volatility index. The quick ratio increased from 1.88 to 5.78.
D
Sell
11/16/2020Downgrade
PharmaCyte Biotech, Inc. (PMCB) was downgraded to D- from D on 11/16/2020 due to a decline in the volatility index.
PharmaCyte Biotech, Inc. (PMCB) was downgraded to D- from D on 11/16/2020 due to a decline in the volatility index.
D
Sell
10/29/2020Upgraded
PharmaCyte Biotech, Inc. (PMCB) was upgraded to D from D- on 10/29/2020 due to an increase in the volatility index.
PharmaCyte Biotech, Inc. (PMCB) was upgraded to D from D- on 10/29/2020 due to an increase in the volatility index.
D
Sell
10/12/2020Downgrade
PharmaCyte Biotech, Inc. (PMCB) was downgraded to D- from D on 10/12/2020 due to a decline in the total return index and volatility index.
PharmaCyte Biotech, Inc. (PMCB) was downgraded to D- from D on 10/12/2020 due to a decline in the total return index and volatility index.
D
Sell
8/10/2020Upgraded
PharmaCyte Biotech, Inc. (PMCB) was upgraded to D from D- on 8/10/2020 due to an increase in the valuation index.
PharmaCyte Biotech, Inc. (PMCB) was upgraded to D from D- on 8/10/2020 due to an increase in the valuation index.
D
Sell
6/18/2020Downgrade
PharmaCyte Biotech, Inc. (PMCB) was downgraded to D- from D on 6/18/2020 due to a decline in the total return index and volatility index.
PharmaCyte Biotech, Inc. (PMCB) was downgraded to D- from D on 6/18/2020 due to a decline in the total return index and volatility index.
D
Sell
5/1/2020Upgraded
PharmaCyte Biotech, Inc. (PMCB) was upgraded to D from D- on 5/1/2020 due to an increase in the total return index, volatility index and valuation index.
PharmaCyte Biotech, Inc. (PMCB) was upgraded to D from D- on 5/1/2020 due to an increase in the total return index, volatility index and valuation index.
D
Sell
2/4/2020Upgraded
PharmaCyte Biotech, Inc. (PMCB) was upgraded to D- from E+ on 2/4/2020 due to an increase in the volatility index and total return index.
PharmaCyte Biotech, Inc. (PMCB) was upgraded to D- from E+ on 2/4/2020 due to an increase in the volatility index and total return index.
E
Sell
12/17/2019Downgrade
PharmaCyte Biotech, Inc. (PMCB) was downgraded to E+ from D- on 12/17/2019 due to a decline in the total return index, valuation index and volatility index.
PharmaCyte Biotech, Inc. (PMCB) was downgraded to E+ from D- on 12/17/2019 due to a decline in the total return index, valuation index and volatility index.
D
Sell
11/29/2019Upgraded
PharmaCyte Biotech, Inc. (PMCB) was upgraded to D- from E+ on 11/29/2019 due to an increase in the valuation index.
PharmaCyte Biotech, Inc. (PMCB) was upgraded to D- from E+ on 11/29/2019 due to an increase in the valuation index.
E
Sell
10/30/2019Downgrade
PharmaCyte Biotech, Inc. (PMCB) was downgraded to E+ from D- on 10/30/2019 due to a decline in the valuation index and volatility index.
PharmaCyte Biotech, Inc. (PMCB) was downgraded to E+ from D- on 10/30/2019 due to a decline in the valuation index and volatility index.
D
Sell
10/15/2019Upgraded
PharmaCyte Biotech, Inc. (PMCB) was upgraded to D- from E+ on 10/15/2019 due to an increase in the total return index and valuation index.
PharmaCyte Biotech, Inc. (PMCB) was upgraded to D- from E+ on 10/15/2019 due to an increase in the total return index and valuation index.
E
Sell
9/20/2019Downgrade
PharmaCyte Biotech, Inc. (PMCB) was downgraded to E+ from D- on 9/20/2019 due to a decline in the solvency index and valuation index. The quick ratio declined from 0.69 to 0.54.
PharmaCyte Biotech, Inc. (PMCB) was downgraded to E+ from D- on 9/20/2019 due to a decline in the solvency index and valuation index. The quick ratio declined from 0.69 to 0.54.
D
Sell
9/10/2019Upgraded
PharmaCyte Biotech, Inc. (PMCB) was upgraded to D- from E+ on 9/10/2019 due to an increase in the total return index and valuation index.
PharmaCyte Biotech, Inc. (PMCB) was upgraded to D- from E+ on 9/10/2019 due to an increase in the total return index and valuation index.
E
Sell
8/2/2019Downgrade
PharmaCyte Biotech, Inc. (PMCB) was downgraded to E+ from D- on 8/2/2019 due to a decline in the volatility index.
PharmaCyte Biotech, Inc. (PMCB) was downgraded to E+ from D- on 8/2/2019 due to a decline in the volatility index.
D
Sell
7/17/2019Upgraded
PharmaCyte Biotech, Inc. (PMCB) was upgraded to D- from E+ on 7/17/2019 due to an increase in the total return index and volatility index.
PharmaCyte Biotech, Inc. (PMCB) was upgraded to D- from E+ on 7/17/2019 due to an increase in the total return index and volatility index.
E
Sell
6/18/2019Downgrade
PharmaCyte Biotech, Inc. (PMCB) was downgraded to E+ from D- on 6/18/2019 due to a large decline in the total return index, volatility index and solvency index.
PharmaCyte Biotech, Inc. (PMCB) was downgraded to E+ from D- on 6/18/2019 due to a large decline in the total return index, volatility index and solvency index.
D
Sell
9/28/2018Upgraded
PharmaCyte Biotech, Inc. (PMCB) was upgraded to D- from E+ on 9/28/2018 due to a significant increase in the solvency index, growth index and total return index.
PharmaCyte Biotech, Inc. (PMCB) was upgraded to D- from E+ on 9/28/2018 due to a significant increase in the solvency index, growth index and total return index.
E
Sell
9/13/2018Downgrade
PharmaCyte Biotech, Inc. (PMCB) was downgraded to E+ from D- on 9/13/2018 due to a significant decline in the solvency index, efficiency index and valuation index.
PharmaCyte Biotech, Inc. (PMCB) was downgraded to E+ from D- on 9/13/2018 due to a significant decline in the solvency index, efficiency index and valuation index.
D
Sell
1/5/2018Upgraded
PharmaCyte Biotech, Inc. (PMCB) was upgraded to D- from E+ on 1/5/2018 due to an increase in the total return index and volatility index.
PharmaCyte Biotech, Inc. (PMCB) was upgraded to D- from E+ on 1/5/2018 due to an increase in the total return index and volatility index.
E
Sell
12/20/2017Downgrade
PharmaCyte Biotech, Inc. (PMCB) was downgraded to E+ from D- on 12/20/2017 due to a decline in the growth index, total return index and volatility index. Operating cash flow declined 70.64% from -$935.6 to -$1.6M, EBIT declined 7.46% from -$1.69M to -$1.81M, and earnings per share declined from -$0.0018 to -$0.0019.
PharmaCyte Biotech, Inc. (PMCB) was downgraded to E+ from D- on 12/20/2017 due to a decline in the growth index, total return index and volatility index. Operating cash flow declined 70.64% from -$935.6 to -$1.6M, EBIT declined 7.46% from -$1.69M to -$1.81M, and earnings per share declined from -$0.0018 to -$0.0019.
D
Sell
5/16/2016Upgraded
PharmaCyte Biotech, Inc. (PMCB) was upgraded to D- from E+ on 5/16/2016 due to an increase in the volatility index.
PharmaCyte Biotech, Inc. (PMCB) was upgraded to D- from E+ on 5/16/2016 due to an increase in the volatility index.
E
Sell
4/29/2016Downgrade
PharmaCyte Biotech, Inc. (PMCB) was downgraded to E+ from D- on 4/29/2016 due to a noticeable decline in the total return index and volatility index.
PharmaCyte Biotech, Inc. (PMCB) was downgraded to E+ from D- on 4/29/2016 due to a noticeable decline in the total return index and volatility index.
D
Sell
4/13/2016Upgraded
PharmaCyte Biotech, Inc. (PMCB) was upgraded to D- from E+ on 4/13/2016 due to an increase in the volatility index.
PharmaCyte Biotech, Inc. (PMCB) was upgraded to D- from E+ on 4/13/2016 due to an increase in the volatility index.
E
Sell
3/21/2016Downgrade
PharmaCyte Biotech, Inc. (PMCB) was downgraded to E+ from D- on 3/21/2016 due to a decline in the valuation index.
PharmaCyte Biotech, Inc. (PMCB) was downgraded to E+ from D- on 3/21/2016 due to a decline in the valuation index.
D
Sell
3/11/2016Downgrade
PharmaCyte Biotech, Inc. (PMCB) was downgraded to D- from D on 3/11/2016 due to a significant decline in the volatility index, total return index and solvency index.
PharmaCyte Biotech, Inc. (PMCB) was downgraded to D- from D on 3/11/2016 due to a significant decline in the volatility index, total return index and solvency index.
D
Sell
7/31/2015Downgrade
PharmaCyte Biotech, Inc. (PMCB) was downgraded to D from D+ on 7/31/2015 due to a noticeable decline in the efficiency index, growth index and total return index. Total capital declined 4.99% from $6.25M to $5.94M.
PharmaCyte Biotech, Inc. (PMCB) was downgraded to D from D+ on 7/31/2015 due to a noticeable decline in the efficiency index, growth index and total return index. Total capital declined 4.99% from $6.25M to $5.94M.
D
Sell
6/26/2015Upgraded
PharmaCyte Biotech, Inc. (PMCB) was upgraded to D+ from D on 6/26/2015 due to an increase in the volatility index and valuation index.
PharmaCyte Biotech, Inc. (PMCB) was upgraded to D+ from D on 6/26/2015 due to an increase in the volatility index and valuation index.
D
Sell
4/10/2015Downgrade
PharmaCyte Biotech, Inc. (PMCB) was downgraded to D from D+ on 4/10/2015 due to a decline in the valuation index and total return index.
PharmaCyte Biotech, Inc. (PMCB) was downgraded to D from D+ on 4/10/2015 due to a decline in the valuation index and total return index.
D
Sell
3/26/2015Upgraded
PharmaCyte Biotech, Inc. (PMCB) was upgraded to D+ from D on 3/26/2015 due to an increase in the growth index and valuation index.
PharmaCyte Biotech, Inc. (PMCB) was upgraded to D+ from D on 3/26/2015 due to an increase in the growth index and valuation index.
D
Sell
12/16/2014Downgrade
Nuvilex, Inc. (NVLX) was downgraded to D from D+ on 12/16/2014 due to a major decline in the volatility index, solvency index and growth index. The quick ratio declined from 7.8 to 4.17.
Nuvilex, Inc. (NVLX) was downgraded to D from D+ on 12/16/2014 due to a major decline in the volatility index, solvency index and growth index. The quick ratio declined from 7.8 to 4.17.
D
Sell
8/5/2014Upgraded
Nuvilex, Inc. (NVLX) was upgraded to D+ from D on 8/5/2014 due to a large increase in the solvency index, valuation index and total return index. The quick ratio increased from 1.8 to 9.68, and debt to equity declined from 0.04 to 0.02.
Nuvilex, Inc. (NVLX) was upgraded to D+ from D on 8/5/2014 due to a large increase in the solvency index, valuation index and total return index. The quick ratio increased from 1.8 to 9.68, and debt to equity declined from 0.04 to 0.02.
D
Sell
6/25/2014Downgrade
Nuvilex, Inc. (NVLX) was downgraded to D from D+ on 6/25/2014 due to a large decline in the total return index and valuation index.
Nuvilex, Inc. (NVLX) was downgraded to D from D+ on 6/25/2014 due to a large decline in the total return index and valuation index.
NASDAQ
03/12/2025 4:00PM Eastern
Quotes delayed
